Status:
COMPLETED
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
Lead Sponsor:
Belfast Health and Social Care Trust
Collaborating Sponsors:
Queen's University, Belfast
Conditions:
SARS CoV 2 Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokin...
Detailed Description
In a normal reaction to a wound, such as after surgery, there is stimulation of pain nerves (called c-fibres), swelling and clotting. When people are hospitalized with COVID-19 they usually have a cou...
Eligibility Criteria
Inclusion
- Age \>18 years.
- Documented evidence of COVID-19 and symptom onset of 7 days or less
- Acute hypoxia which will be defined as either low resting saturations \<94% or supplementary oxygen to maintain oxygen saturations at \>94%
Exclusion
- Patients known to be pregnant or breastfeeding.
- Patients with unstable ischaemic heart disease or acute stroke
- Patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period
- Patients who refuse to have blood samples taken.
- Known hypersensitivity to Icatibant
- Patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (CPAP).
- Patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline
Key Trial Info
Start Date :
May 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT05407597
Start Date
May 16 2022
End Date
July 7 2023
Last Update
September 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mater Infirmorum Hospital
Belfast, Antrim, United Kingdom, BT14 6AB